Where is KBH's stock going now?
KBH
KB Home Beats
Tuesday, September 22, 2026 4:10:00 PM
KB Home (KBH) reported 3rd Quarter August 2026 earnings of $1.05 per share on revenue of $1.3 billion. The consensus earnings estimate was $0.88 per share on revenue of $1.3 billion. The Earnings Whisper number was $0.85 per share.
The company said it expects fourth quarter revenue of $1.45 billion to $1.65 billion. The current consensus revenue estimate is $1.59 billion for the quarter ending November 30, 2026.
KB Home is one of the largest and most recognized homebuilders in the United States and has built over 650,000 quality homes in our more than 60-year history.
Where is WOR's stock going now?
WOR
Worthington Enterprises reports
Tuesday, September 22, 2026 4:10:00 PM
Worthington Enterprises (WOR) reported 1st Quarter August 2026 earnings of $0.82 per share on revenue of $343.9 million. The consensus earnings estimate was $0.74 per share on revenue of $332.1 million.
Worthington Industries Inc is a metal manufacturing company. It is engaged in steel processing including design & manufacturing steel custom platforms, racks & pallets; manufacturing pressure cylinders including CNG & LPG; & manufacturing engineered cabs.
Where is AYTU's stock going now?
AYTU
Aytu Biopharma reports
Tuesday, September 22, 2026 4:05:00 PM
Aytu Biopharma (AYTU) reported a 4th Quarter June 2026 loss of $0.05 per share on revenue of $16.1 million. The consensus estimate was a loss of $0.22 per share on revenue of $11.6 million.
Aytu BioPharma is a specialty pharmaceutical company with a growing commercial portfolio of prescription therapeutics and consumer health products.
Where is MLKN's stock going now?
MLKN
Millerknoll Beats
Tuesday, September 22, 2026 7:00:00 AM
Millerknoll (MLKN) reported 1st Quarter August 2026 earnings of $0.53 per share on revenue of $923.4 million. The consensus earnings estimate was $0.35 per share on revenue of $942.7 million. The Earnings Whisper number was $0.37 per share.
The company said it expects second-quarter earnings of $0.43 to $0.49 per share on revenue of $972.0 million to $1.012 billion. The current consensus earnings estimate is $0.46 per share on revenue of $1.02 billion for the quarter ending November 30, 2026. The company also said it continues to expect fiscal 2027 earnings of $1.85 to $2.15 per share but now expects revenue of $3.88 billion to $4.03 billion. The company's previous guidance was revenue of $3.93 billion to $4.13 billion, and the current consensus earnings estimate is $2.02 per share on revenue of $4.01 billion for the year ending May 31, 2027.
MillerKnoll is a collective of dynamic brands and one of the largest and most influential modern design companies in the world.
Where is AZO's stock going now?
AZO
Autozone Beats
Tuesday, September 22, 2026 6:55:00 AM
Autozone (AZO) reported 4th Quarter August 2026 earnings of $56.05 per share on revenue of $6.6 billion. The consensus earnings estimate was $54.54 per share on revenue of $6.7 billion. The Earnings Whisper number was $54.26 per share.
AutoZone Inc is a retailer and distributor of automotive replacement parts and accessories in the United States. The Company operates stores which carries an extensive product line for cars, sport utility vehicles, vans and light trucks and among others.
Where is THO's stock going now?
THO
Thor Industries Misses
Tuesday, September 22, 2026 6:30:00 AM
Thor Industries (THO) reported 4th Quarter July 2026 earnings of $0.78 per share on revenue of $2.3 billion. The consensus earnings estimate was $0.93 per share on revenue of $2.2 billion. The Earnings Whisper number was $0.99 per share.
Thor Industries Inc manufactures and sells a range of recreational vehicles and small and mid-size buses in the United States and Canada. The Company’s two reportable segments include towable recreational vehicles and motorized recreational vehicles.
Where is ABVX's stock going now?
ABVX
Abivax Sa ADR reports
Monday, September 21, 2026 4:05:00 PM
Abivax Sa ADR (ABVX) reported a 2nd Quarter June 2026 loss of $1.71 per share on revenue of $1.4 million. The consensus estimate was a loss of $1.08 per share on revenue of $1.9 million.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases
